Azacytidine plus venetoclax to prevent AML coming back
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have favorable-risk AML and are not planning to get an allogeneic stem cell transplant right away
- You are between 18 and 64 years old and currently in your first remission
- You finished remission induction therapy and then 3–4 cycles of cytarabine-based consolidation (high-dose or medium-dose)
- Your health status is fairly good (ECOG 0 to 3) and your heart and organ tests are adequate (bilirubin, liver enzymes, kidney function, and heart pumping strength)
- You can participate safely with the study medicines (including pregnancy prevention if applicable)
- You can understand and sign the informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—for people with acute myeloid leukemia (AML) who cannot have intensive chemotherapy, or whose leukemia has returned after treatment. The goal is to see if this combination helps control the leukemia with manageable side effects.
This study tests whether adding venetoclax to azacitidine after a patient reaches remission helps keep the leukemia from coming back. It is for people with acute myeloid leukemia (AML) who have completed initial treatment and are in their first remission.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Hear when a new Acute Myeloid Leukemia (AML) in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.